Biotech is a tough game in a turbulent market, all bio has taken a brutal beating for anything not on the cusp of commercialisation. Both companies mentioned have seen excellent data, progressed phenomenally in their short years on the market. Hopper has attracted great people to great assets. If he had just gone to insto at 2.8c there would be people whinging at that too.
Ann: Entitlement Offer to raise approximately $10 million, page-45
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
